Agilent Technologies Inc. introduced Agilent SureFISH probes, the next generation of fluorescent in situ hybridization (FISH) assays, delivering a comprehensive menu of the industry’s highest resolution probes for a wide range of molecular analysis applications.
Agilent SureFISH probes deliver better performance compared to existing FISH products. SureFISH probes enable users to specifically detect aberrations in regions of the genome as small as 50kb, as well as aberrations near highly repetitive regions. They provide higher resolution and faster hybridization times than competing technologies and are designed to enable users to meet American College of Medical Genetics guidelines for clinical cytogenetics.
Manufactured at Agilent’s Cedar Creek, Texas, facility, which is registered with the U.S. Food and Drug Administration as a medical device establishment, Agilent SureFISH probes are Class I analyte specific reagents. They are manufactured under Quality Standard Regulations and current Good Manufacturing Practices.
Agilent offers an extensive menu of FISH probes for constitutional and cancer applications. The initial menu includes hundreds of SureFISH probes for the most common regions, to accommodate a wide range of cytogenetic research needs.
